bromine facts

  • Receive alerts:
  • by e-mail
    Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L.
  • via RSS

4 documents for bromine facts
  • 1. The appellants G.D. Searle & Co, the Pharmacia Corporation and Pfizer Inc. are the proprietors of European Patent (UK) 0 679 157. I will refer to them as the patentees. They alleged that that patent had been infringed by Merck & Co Inc. and Merck Sharp & Dohme Limited by amongst other acts the manufacture and sale of a non-steriodal anti-inflammatory (NSAID) sold under the trademark Vioxx, but referred to by Merck as MK-966. 2. Merck accepted that they had carried out the allegedly infringing acts, but denied infringement and submitted that the patent was invalid upon a number of grounds. Pumfrey J upheld those submissions. His decision is challenged by the patentees in this appeal. 3. The appeal involves issues which require knowledge of a difficult area of chemistry. I am ind...

    ... that they will provide the following facts in relation to the in vitro experiments the ... at the carbon atom adjacent R2 by a bromine group or any group that occupies a space as large ...

  • 1. This is the judgment in two actions brought by Ranbaxy (UK) Limited (`Ranbaxy') and an action by Arrow Generics Limited (`Arrow') respectively against Warner-Lambert Company, (`Warner-Lambert'). Warner-Lambert is the owner of European Patent (UK) 0247633 ('633) and of European Patent (UK) 0409281 ('281), which are concerned with atorvastatin, a cholesterol synthesis inhibitor of great commercial importance. The calcium salt is sold under the name Lipitor. 2. In action 2167 Ranbaxy seek a declaration of non-infringement in respect of '633. Both Ranbaxy (in action 2059) and Arrow (in action 3986) seek to revoke '281, which claims atorvastatin calcium. The issues in respect of '281 are common to the latter actions, and the same evidence was relied on both by Ranbaxy and by Arrow. 3. So fa...

    ... substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to ...I shall set out the facts relating to the common general knowledge in the ...

  • 1. This is the trial of three claims for revocation of European Patent (UK) No 0,347,066 (``The Patent'') in the name of the defendant (``Lundbeck''). As a result of an earlier direction, the evidence in each claim stands as evidence in the others and the three claimants have provided a single set of expert reports. For practical purposes I can therefore treat the three claims as a single claim for revocation. 2. The Patent has a priority date of June 1988 and concerns an antidepressant drug called escitalopram. It is sold by Lundbeck which is a comparatively small research based pharmaceutical company located in Denmark. Lundbeck specialises in diseases of the central nervous system. Escitalopram was launched in 2002 and accounts for approximately 60% of Lundbeck's turnover. It is c...

    ... time as the original bond (the carbon-bromine bond) is breaking. A transition state is formed ...The facts were simple: there was a known process. The ...

  • The Secretary of State, in exercise of the powers (as respects regulations 1 to 16 and 18 to 22) conferred on him by sections 15(1) , (2) , (3)(a) , (4)(b) , (5)(a) and (b) , 43(2) and 82(3)(a) of, and paragraphs 3(1) , 6 , 8(1) , 11 , 14 , 15(1) and 16 of Schedule 3 to, the Health and Safety at Work etc. Act 1974(1) (“the 1974 Act”) and for the purpose of giving effect without modifications to proposals submitted to him by the Health and Safety Commission under section 11(2)(d) of the 1974 Act after the carrying out by the said Commission of consultations in accordance with section 50(3) of that Act, and (as respects regulations 17 and 21) under section 2(2) of the European Communities Act 1972(2) being the Minister designated(3) for the purposes of the said section 2(2) both in relation

    ... arise) , information of and advice on the facts of the emergency, of the steps to be taken and, ...7 1011. Bi-213. 7 1011. Bi-214. 1 1012. Bromine. Br-74. 8 1011. Br-74 m. 6 1011. Br-75. 2 1012. ...

ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2014, vLex. All Rights Reserved.

Contents in vLex United Kingdom

Explore vLex

For Professionals

For Partners

Company